339 related articles for article (PubMed ID: 30925751)
41. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
42. Vascular endothelial growth factor signaling in development and disease.
Karaman S; Leppänen VM; Alitalo K
Development; 2018 Jul; 145(14):. PubMed ID: 30030240
[TBL] [Abstract][Full Text] [Related]
43. Peripheral vascular disease: preclinical models and emerging therapeutic targeting of the vascular endothelial growth factor ligand-receptor system.
Ganta VC; Annex BH
Expert Opin Ther Targets; 2021 May; 25(5):381-391. PubMed ID: 34098826
[No Abstract] [Full Text] [Related]
44. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.
Shibuya M
J Biochem; 2013 Jan; 153(1):13-9. PubMed ID: 23172303
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
Dias S; Hattori K; Heissig B; Zhu Z; Wu Y; Witte L; Hicklin DJ; Tateno M; Bohlen P; Moore MA; Rafii S
Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10857-62. PubMed ID: 11553814
[TBL] [Abstract][Full Text] [Related]
46. VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro.
Beazley-Long N; Hua J; Jehle T; Hulse RP; Dersch R; Lehrling C; Bevan H; Qiu Y; Lagrèze WA; Wynick D; Churchill AJ; Kehoe P; Harper SJ; Bates DO; Donaldson LF
Am J Pathol; 2013 Sep; 183(3):918-29. PubMed ID: 23838428
[TBL] [Abstract][Full Text] [Related]
47. Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1.
Failla CM; Carbo M; Morea V
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29702562
[TBL] [Abstract][Full Text] [Related]
48. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.
Rahimi N; Golde TE; Meyer RD
Cancer Res; 2009 Mar; 69(6):2607-14. PubMed ID: 19276374
[TBL] [Abstract][Full Text] [Related]
49. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
Gunningham SP; Currie MJ; Han C; Robinson BA; Scott PA; Harris AL; Fox SB
Clin Cancer Res; 2000 Nov; 6(11):4278-86. PubMed ID: 11106244
[TBL] [Abstract][Full Text] [Related]
50. VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo.
Rennel ES; Varey AH; Churchill AJ; Wheatley ER; Stewart L; Mather S; Bates DO; Harper SJ
Br J Cancer; 2009 Oct; 101(7):1183-93. PubMed ID: 19707198
[TBL] [Abstract][Full Text] [Related]
51. The VEGF-A exon 8 splicing-sensitive fluorescent reporter mouse is a novel tool to assess the effects of splicing regulatory compounds
Stevens M; Star E; Lee M; Innes E; Li L; Bowler E; Harper S; Bates DO; Oltean S
RNA Biol; 2019 Dec; 16(12):1672-1681. PubMed ID: 31432737
[TBL] [Abstract][Full Text] [Related]
52. VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases.
Shibuya M
Endocr Metab Immune Disord Drug Targets; 2015; 15(2):135-44. PubMed ID: 25772179
[TBL] [Abstract][Full Text] [Related]
53. Snake venom VEGF Vammin induces a highly efficient angiogenic response in skeletal muscle via VEGFR-2/NRP specific signaling.
Toivanen PI; Nieminen T; Laakkonen JP; Heikura T; Kaikkonen MU; Ylä-Herttuala S
Sci Rep; 2017 Jul; 7(1):5525. PubMed ID: 28717175
[TBL] [Abstract][Full Text] [Related]
54. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer.
Guo S; Gonzalez-Perez RR
PLoS One; 2011; 6(6):e21467. PubMed ID: 21731759
[TBL] [Abstract][Full Text] [Related]
55. Gene expression profile of vascular endothelial growth factor (VEGF) and its receptors in various cell types of the canine lymph node using laser capture microdissection (LCM).
Jais A; Klein D; Wolfesberger B; Walter I
Vet Immunol Immunopathol; 2011 Apr; 140(3-4):207-14. PubMed ID: 21211854
[TBL] [Abstract][Full Text] [Related]
56. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.
Chung ES; Chauhan SK; Jin Y; Nakao S; Hafezi-Moghadam A; van Rooijen N; Zhang Q; Chen L; Dana R
Am J Pathol; 2009 Nov; 175(5):1984-92. PubMed ID: 19808642
[TBL] [Abstract][Full Text] [Related]
57. Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors.
Pavlakovic H; Becker J; Albuquerque R; Wilting J; Ambati J
Ann N Y Acad Sci; 2010 Oct; 1207 Suppl 1(Suppl 1):E7-15. PubMed ID: 20961309
[TBL] [Abstract][Full Text] [Related]
58. Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis.
Man XY; Yang XH; Cai SQ; Yao YG; Zheng M
Mol Med; 2006; 12(7-8):127-36. PubMed ID: 17088944
[TBL] [Abstract][Full Text] [Related]
59. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.
Gille H; Kowalski J; Li B; LeCouter J; Moffat B; Zioncheck TF; Pelletier N; Ferrara N
J Biol Chem; 2001 Feb; 276(5):3222-30. PubMed ID: 11058584
[TBL] [Abstract][Full Text] [Related]
60. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
